| BIOGEN INC. DL -,0005 | 220.000 / -0.25% |
| Date/Time | 01/22 / 22:59 |
| Chg. / Chg.(%) | -0.550 / -0.25% |
| Bid | 220.000 |
| Ask | 221.150 |
| Open | 220.550 |
| Previous Close | 220.550 |
| High | 224.700 |
| Low | 219.700 |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | 5902 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | Lang & Schwarz |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 269.4400 |  |
691,106 |
| IEX | 269.37 | |
36,610 |
| Cboe US | 269.57 | |
24,969 |
| London Inter.. | 270.23 | |
1,739 |
| Xetra | 221.10 | |
1,633 |
| TradeGate | 221.600 | |
1,166 |
| Stuttgart | 220.100 | |
115 |
| Frankfurt | 220.9500 | |
68 |
| Vienna Globa.. | 221.15 | |
51 |
| München | 222.10 | |
10 |
| gettex | 221.500 | |
5 |
| Hamburg | 220.60 | |
0 |
| Düsseldorf | 221.65 | |
0 |
| Berlin | 222.10 | |
0 |
| Hannover | 220.60 | |
0 |
| Lang & Schwa.. | 220.000 | |
|
| Mexico | 5,375.00 | |
20 |
News
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
01/11/2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
01/08/2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
12/21/2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
12/17/2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
12/10/2020 / 04:30 - GlobeNewswire
Real-time